inVentiv Health has signed a definitive agreement to acquire the i3 clinical development businesses from Ingenix. The transaction, subject to customary closing conditions, is expected to close in 1H11.

The three businesses will retain the i3 brand and will be aligned with inVentiv’s other clinical development offerings. Glenn Bilawsky will remain chief executive officer of i3. The commercialization, safety, regulatory and late phase service offerings will be launched as Ingenix Life Sciences division, led by Lee Valenta, chief operating officer of Ingenix.